Sweden Antifungal Drugs Market Size & Outlook, 2023-2030
Sweden antifungal drugs market, 2018-2030 (US$M)
Related Markets
Sweden antifungal drugs market highlights
- The Sweden antifungal drugs market generated a revenue of USD 154.6 million in 2023 and is expected to reach USD 198.9 million by 2030.
- The Sweden market is expected to grow at a CAGR of 3.7% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 154.6 million |
| Market revenue in 2030 | USD 198.9 million |
| Growth rate | 3.7% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Sweden accounted for 1.0% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,215.7 million by 2030.
Azoles was the largest segment with a revenue share of 47.99% in 2023. Horizon Databook has segmented the Sweden antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Key players in the country are engaged in product launches and strategic collaborations. For instance, in November 2021, Moberg Pharma AB and Allderma AB entered into a collaborative agreement for the launch of MOB-015 (for nail fungus) in Sweden.
Under this collaboration, Alderman is responsible for distribution, marketing, and sales in Sweden. Through this product launch, the company aims to reach a market-leading position in the country. Such strategic initiatives by key market players are expected to fuel Sweden's market.
Medical Products Agency (Läkemedelsverket) (MPA) and the Regulations issued by the Dental and Pharmaceutical Benefits Agency (Tandvårds-och läkemedelsförmånsverket) (DPBA) are the main national regulatory authorities in the country.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Sweden antifungal drugs market size, by drug class, 2018-2030 (US$M)
Sweden Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
